Knowledge HQ

This study evaluates PRAME-specific TCR-Ts co-expressing a chimeric PD1-41BB receptor. These cells showed enhanced cytotoxicity against PRAME+ tumors in vitro and in vivo. G-Rex were used for the 10-day expansion phase of T-cells after transduction.

This study evaluates CAR/CXCR5-T cells for treating SIV infection in rhesus macaques. The cells homed to lymphoid follicles and reduced viral loads. Transduced T cells were expanded in G-Rex 500M-CS containers and 6-well plates during manufacturing.

SARS-CoV-2-specific T cells were generated from convalescent donors for adoptive immunotherapy. These cells recognized multiple viral variants and provided broad HLA coverage. G-Rex culture vessels were used to culture and expand the peptide-stimulated PBMCs.

The HydrAd platform uses helper-dependent adenovirus (HDAd) vectors to express multiple immunomodulatory transgenes for cancer therapy. It was evaluated with T cells and NK cells. NK cells used in the study were expanded in G-Rex cell culture devices.

A nonviral CRISPR/Cas9 method using plasmid donor DNA was developed for efficient gene knock-in in primary human T cells. The method was used for TCR and CAR integration. G-Rex 24-well plates were used to culture and expand the edited T cells.

This study identifies CISH as a negative regulator of T cell effector function. CRISPR/Cas9 deletion of CISH improved TIL neoantigen recognition and efficacy. Clinical-scale manufacturing of CISH KO TILs utilized G-Rex 100 for the rapid expansion protocol (REP).

This poster describes the development of cord blood-derived CD38 CAR-NK cells with CRISPR/Cas9-mediated CD38 knockout. These cells demonstrated potent activity against multiple myeloma. G-Rex 6M plates were utilized to achieve significant cell expansion (approx. 400-fold).

This study characterizes the pharmacology of the Tmod system, which uses an activator (CAR/TCR) and a blocker (LIR-1 based) to discriminate tumor from normal cells. Primary T cells transduced with Tmod constructs were cultured and recovered in G-Rex 24-well plates.

A Phase 1 trial evaluated AGT103-T, a genetically modified Gag-specific CD4+ T cell product for HIV. The therapy was safe and increased Gag-specific T cell responses. G-Rex 500M-CS containers were used for the static culture expansion of the cell product during manufacturing.

This Phase I trial evaluated the safety of ex vivo expanded, off-the-shelf NK cells from unrelated donors in patients with malignancies. The NK cells were expanded using a feeder cell platform in G-Rex. The treatment was safe with no GVHD and showed signs of efficacy.

This study develops a fully murine CD105 CAR-T cell system to study CAR-T biology in immunocompetent mice. It also validates a human CD105 CAR against melanoma and AML. Human CAR-T cells were expanded in G-Rex 6M well plates following sorting.

This study analyzes immune kinetics in oral cancer patients treated with neoadjuvant ICB, finding that tissue-resident memory T cells are key early responders. G-Rex 10 were used to expand T cells for T-Scan antigen discovery screens to identify tumor-associated targets.